ArticleOpen forum infectious diseases2019
Incidence and Outcome of Severe and Nonsevere Thrombocytopenia Associated With Zika Virus Infection-Puerto Rico, 2016.
Article in Open forum infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- SARS-CoV-2 infection-induced immune thrombocytopenia: a systematic review of current reports.Annals of hematology · 2024Pooled it
- Clinical manifestations and health outcomes associated with Zika virus infections in adults: A systematic review.PLoS neglected tropical diseases · 2021Pooled it
- Measuring the global burden of chikungunya and Zika viruses: A systematic review.PLoS neglected tropical diseases · 2021Pooled it
- Clinical Manifestations and Immunological Impacts in Co-Infections and Sequential Infections of SARS-CoV-2 and Arboviruses.Current microbiology · 2026Review
- Coinfection with Respiratory Pathogens and Dengue Disease Severity in Puerto Rico, 2012-2024.The American journal of tropical medicine and hygiene · 2025Article
- A decade later, what have we learned from the Zika epidemic in children with intrauterine exposure?Lancet (London, England) · 2025Review
- Severe exacerbation of immune thrombocytopenia and COVID-19: the favorable response to corticosteroid-based therapy-a case report.Annals of hematology · 2021Article
- Article
- Thrombocytopenia in Virus Infections.Journal of clinical medicine · 2021Review
- Hide and Seek: The Interplay Between Zika Virus and the Host Immune Response.Frontiers in immunology · 2021Review
- Epidemiologic and spatiotemporal trends of Zika Virus disease during the 2016 epidemic in Puerto Rico.PLoS neglected tropical diseases · 2020Article
- Patterns of signs, symptoms, and laboratory values associated with Zika, dengue, and undefined acute illnesses in a dengue endemic region: Secondary analysis of a prospective cohort study in southern Mexico.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2020Article
- Article
- Impact of delayed treatment on exacerbations of multiple sclerosis among Puerto Rican patients.Surgical neurology international · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundZika virus (ZIKV) infection has been associated with severe thrombocytopenia. We describe the incidence, clinical manifestations, and outcomes of patients with ZIKV infection and thrombocytopenia.
methodsWe reviewed medical records of patients with ZIKV infection and thrombocytopenia (platelet count <100 ×10
resultsOf 37 878 patients with ZIKV infection, 47 (0.1%) had thrombocytopenia in the absence of an alternative etiology (1.4 cases/100 000 population), including 12 with severe thrombocytopenia. Most patients with thrombocytopenia were adult (77%) and male (53%). Platelet nadir occurred a median (range) of 6 (1-16) and 5 (0-34) days after symptom onset for patients with severe and nonsevere thrombocytopenia, respectively. Among patients with severe thrombocytopenia, all had bleeding, 33% were admitted to the intensive care unit, and 8% died; 50% were treated for ITP. Among 5 patients with severe thrombocytopenia who received intravenous immunoglobulin, the median platelet count increase (range) was 112 (65-202) ×10
conclusionsPatients with severe thrombocytopenia and ZIKV infection experienced prominent acute morbidity. Consistent with recommended management, administration of ITP treatments to such patients may be more efficacious than platelet transfusion in resolving thrombocytopenia. Severe thrombocytopenia should be considered a rare outcome of ZIKV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.